Study On Changes Of TNF-α And IL-6 In Neonates With Hypoxic-ischemic Encephalopathy Treated By GM1

Objectives:To observe the clinical efficacy and the changes of TNF-αand IL-6 in neonates with hypoxic-ischemic encephalopathy treated by exongenous monosialoganglioside before and after treatment , to discuss the relation with monosialoganglioside and the changes of TNF-αand IL-6, to provide further clinical and theoretical basis for comprehensive evaluation of GM1 protective effect in brain damage.Methods:sixty inpatients with moderate HIE in our Neonatal Department were randomly divided into GM1 group and control group. There are thirty children in each group. Two groups were all treated by routine medicine. in addition , informed consent by family members,the chlidren of GM1 group were added with monosialoganglioside 20mg and 5% glucose injection 20ml by intravenous drip once a day.The chlidren of control group were added with citicoline 0.125g and 5% glucose injection 20ml by intravenous drip once a day too. Two groups started to be treated when they were in hospital in the first day .and kept on for 7 days.Two groups were carried out neonatal behavioral neurological assessment (NBNA) score before and after treatment. And the concentration of TNF-αand IL-6 in serum were measured in the first and eighth day by enzyme-linked immunosorbent assay (ELISA) .what's more, observed their changes and clinical efficacy after treatment.Results:GM1 group was significantly higher than control in the total effective rate(P<0.05). After treatment, the time of recovery in GM1 group was shorter than that of in control group with consciousness,muscular tension and primitive reflexes. GM1 group was significantly higher than control by NBNA score (P<0.05). TNF-α, IL-6 of GM1 group in serum was lower than that of in control group after treament. And there was significant difference (P<0.05). TNF-αwas negatively correlated with NBNA score(r=-0.136,P<0.05).IL-6 was negatively correlated with NBNA score too(r=-0.108,P<0.05). Conclusion:1. The recent clinical efficacy of GM1 in HIE was superior to citicoline.2. GM1 may inhibit level of TNF-αand IL-6 in serum to reduce brain damage in newborn with HIE.3. TNF-αand IL-6 in serum can be used as biochemical indicators with clinical prognosis of HIE .